ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0467

Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab

Cathy Melong Pianta1, Kim Lauper1, Delphine Courvoisier1, Tim Cunningham2, Daniéle Allali3 and Axel Finckh4, 1Division of rheumatology, Geneva University Hospitals, Geneva, Switzerland, 2Private practice, Geneva, Geneva, Switzerland, 3Division of immunology, Geneva University Hospitals, Geneva, 4Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland

Meeting: ACR Convergence 2020

Keywords: COVID-19

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Friday, November 6, 2020

Session Title: Patient Outcomes, Preferences, & Attitudes I: COVID-19 (0464–0468)

Session Type: Abstract Session

Session Time: 5:00PM-5:50PM

Background/Purpose: The prevalence of anti-SARS-CoV-2 IgG infection was estimated at 9.7% in the Geneva population end of April 2020. (1) Immunosuppressed patients may be at increased risk of developing severe forms of COVID-19. It is unknown whether the increasing risk is due to immune-mediated diseases by themselves or to specific immunosuppressive therapies. We postulated that long-lasting cell-depleting therapies may increase the risk of severe COVID-19 more than targeted anti-cytokine therapies.

Methods: We included all patients who received infliximab or rituximab at the Rheumatology Division of the Geneva University Hospitals between September 1st 2019 and February 29, 2020 (last 6 months). We called each patient and administrated a questionnaire with predefined questions on incident COVID-19 symptoms and COVID-19 diagnosis between March 1st, 2020 and end of May 2020, which represents the first wave of the COVID 19 pandemic in Switzerland.

We compared patient characteristics using Wilcoxon test for continuous variables and Fisher test for categorical variables. We calculated prevalence, incidence and their crude and adjusted prevalence and incidence ratio with generalised estimating equations using a Poisson distribution. We adjusted the prevalence and incidence ratio by quartiles of a propensity score based on age, gender, disease (rheumatoid arthritis (RA) vs other), smoking and presence of a comorbidity.

Results: During the study period, 151 patients received either rituximab (RTX, n=86) or infliximab (IFX, n=65). We were able to retrieve complete COVID-19 information from 142 (94.0%) patients. RTX patients were older than IFX patients with an average of 56.6 (47.2, 67.4), and significant different in the underlying diagnoses (more RA on RTX and more spondyloarthritis (SpA) on IFX) (Table 1).

Overall, 15 (10.5%) patients have reported symptoms of plausible COVID-19; 9 (13.8%) on IFX and 6 (7.0%) on RTX (p= 0.18). All 15 patients (RTX=7, IFX=8) were tested for Sars-Cov2 using nasopharyngeal swab PCR.  Three patient developed severe pulmonary manifestations requiring hospitalisation (two hospitalized in intensive care units, one died). These patient’s were 74, 62, 45 years of age respectively, without any of the established at risk comorbidities, but tobacco smoking.

During this first wave of COVID-19 epidemic, the prevalence of plausible COVID-19 in these immunosuppressed patients was 13.8% (95%CI: 7.5-25.4) on IFX, compared to 7.0% (95%CI: 3.2-15.1) on RTX (crude p=0.17, adjusted p=0.03). The incidence rate of COVID-19 was 2.10 (95% CI: 0.94-3.92) cases/1000 patients-days on IFX, compared to 0.97 (0.35-2.10) cases/1000 patients-days on RTX, a significantly increased rate with IFX compared to RTX (crude p< 0.001, adjusted p=0.03).

The incidence rate of severe COVID-19 was null on IFX (95%CI: 0.0-0.76) compared to 0.47 (0.10-1.38) cases/1000 patients-days on RTX. On RTX, tree out of six patients had a severe evolution compared to zero out of 9 patients on  IFX  (p=0.04).

Conclusion: The incidence of severe COVID-19 tended to be higher in patients on RTX compared to IFX. The study is ongoing, with an analysis of a broader patient sample.


Disclosure: C. Melong Pianta, None; K. Lauper, None; D. Courvoisier, None; T. Cunningham, None; D. Allali, None; A. Finckh, Pfizer, 2, 8, Bristol-Myers Squibb Company, 2, 8, Eli Lilly, 2, 8, AbbVie, 8, AB2Bio, 8, Sandoz, 8, Sanofi, 8.

To cite this abstract in AMA style:

Melong Pianta C, Lauper K, Courvoisier D, Cunningham T, Allali D, Finckh A. Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/incidence-of-covid-19-in-patients-treated-with-infliximab-compared-to-patients-treated-with-rituximab/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-covid-19-in-patients-treated-with-infliximab-compared-to-patients-treated-with-rituximab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.